Bessemer Group’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$590K Buy
9,380
+1,218
+15% +$84.8K ﹤0.01% 1084
2025
Q4
$542K Sell
8,162
-615,708
-99% -$39.8M ﹤0.01% 1113
2025
Q3
$42M Sell
623,870
-319,073
-34% -$25.3M 0.06% 195
2025
Q2
$82.3M Sell
942,943
-6,148
-0.6% -$482K 0.13% 166
2025
Q1
$64.8M Buy
949,091
+25,459
+3% +$2.08M 0.12% 167
2024
Q4
$71.8M Sell
923,632
-40,276
-4% -$2.98M 0.12% 162
2024
Q3
$64.6M Buy
963,908
+14,954
+2% +$1.23M 0.11% 171
2024
Q2
$108M Sell
948,954
-6,207
-0.6% -$785K 0.19% 132
2024
Q1
$132M Sell
955,161
-372,228
-28% -$46.8M 0.24% 117
2023
Q4
$165M Buy
1,327,389
+285,136
+27% +$29.1M 0.32% 88
2023
Q3
$97.2M Buy
1,042,253
+2,160
+0.2% +$243K 0.21% 131
2023
Q2
$134M Buy
1,040,093
+25,061
+2% +$3.03M 0.28% 97
2023
Q1
$118M Buy
1,015,032
+9,603
+1% +$1.07M 0.28% 105
2022
Q4
$114M Buy
1,005,429
+23,173
+2% +$2.54M 0.28% 115
2022
Q3
$79.1M Buy
982,256
+31,443
+3% +$2.66M 0.21% 134
2022
Q2
$70.9M Sell
950,813
-203,647
-18% -$18.6M 0.18% 145
2022
Q1
$148M Buy
1,154,460
+129,120
+13% +$14.1M 0.31% 100
2021
Q4
$138M Buy
1,025,340
+1,996
+0.2% +$287K 0.28% 115
2021
Q3
$140M Buy
1,023,344
+436
+0% +$55K 0.3% 110
2021
Q2
$109M Buy
1,022,908
+93,012
+10% +$8.93M 0.24% 140
2021
Q1
$83.5M Buy
929,896
+177,000
+24% +$16.6M 0.2% 148
2020
Q4
$69.6M Sell
752,896
-372
-0% -$33.2K 0.18% 147
2020
Q3
$77.6M Buy
753,268
+344,472
+84% +$36M 0.23% 116
2020
Q2
$41.4M Buy
+408,796
New +$36.6M 0.13% 149
2019
Q2
Sell
-120
Closed -$4K 1677
2019
Q1
$4K Sell
120
-68
-36% -$2.39K ﹤0.01% 1621
2018
Q4
$6K Hold
188
﹤0.01% 1737
2018
Q3
$7K Buy
+188
New +$5.83K ﹤0.01% 1639
2017
Q4
Sell
-1,060
Closed -$13K 1720
2017
Q3
$13K Hold
1,060
﹤0.01% 1564
2017
Q2
$19K Buy
+1,060
New +$19.6K ﹤0.01% 1487
2015
Q3
Sell
-320
Closed -$6K 1646
2015
Q2
$6K Buy
+320
New +$5.62K ﹤0.01% 1320

Other funds holding DXCM

Bessemer Group's DXCM Position: Q1 2026 in Review

Bessemer Group increased its DexCom (DXCM) stake by 15% in Q1 2026, buying an estimated $84.8K and bringing the position to 9,380 shares worth $590K. The position accounts for ﹤0.01% of the portfolio, ranked #1084.

Bessemer Group first reported a position in DXCM in Q2 2015 and has held it in 30 quarters since. The position peaked at $165M in Q4 2023. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • Bessemer Group held 9,380 shares of DexCom worth $590K as of Q1 2026.
  • Bessemer Group bought 1,218 DexCom shares in Q1 2026, an estimated $84.8K.
  • DexCom made up ﹤0.01% of Bessemer Group's portfolio in Q1 2026, its #1084 holding.
  • Bessemer Group first reported a position in DexCom in Q2 2015 and has held it in 30 quarters since.
  • Bessemer Group's DexCom position peaked at $165M in Q4 2023.
  • 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.